EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of fremanezumab treatment in patients with migraine headache

Shoji Kikui iD, Danno Daisuke, Junichi Miyahara, Hanako Sugiyama, Kuniko Ota, Kenji Murakata, Yoshihiro Kashiwaya, Takao Takeshima

Pain Medicine · 2024

DOI: 10.1093/pm/pnae050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pain Medicine, 2024. Verfasst von Shoji Kikui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology & Headache Center, Tominaga Hospital, Osaka City, Japan. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of fremanezumab for migraine prevention.

Design

Retrospective, single-center, real-world study.

Setting

Regional tertiary headache center in Japan. Subjects Adult individuals with migraine (n = 165, male = 17, female = 148; average age = 45.5 ± 16.0 years) who received fremanezumab between September 2021 and August 2022.

Methods

Fremanezumab was administered subcutaneously at a monthly dose of 225 mg or quarterly dose of 675 mg based on patient preferences. Patients received fremanezumab treatment for up to 1 year unless it was discontinued. Monthly data were collected on migraine days, headache days, and days requiring acute medication.

Results

Of the 165 patients, 125 (75.7%) received fremanezumab as their first anti-calcitonin gene-related peptide-related antibody drug. Significant reductions in monthly migraine days, headache days, and days requiring acute medication were observed in those with episodic and chronic migraines. The baseline monthly headache days was 8.1 ± 4.0 in the episodic migraine group, which reduced to 6.1 ± 4.8, 5.8 ± 4.4, 4.7 ± 3.6, and 4.6 ± 3.3 days at 1, 3, 6, and 12 months, respectively; in the chronic migraine group, the baseline monthly headache days was 20.9 ± 6.1, which reduced to 17.0 ± 8.9, 15.0 ± 9.2, 13.0 ± 7.7, and 12.0 ± 9.1 days at 1, 3, 6, and 12 months, respectively. Treatment benefits were enhanced after 6 months of administering fremanezumab in the chronic migraine group.

Conclusions

In this real-world study of patients with migraine, fremanezumab appears to be effective and safe. Further studies are required to identify additional predictors of treatment success and failure with fremanezumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersHumansMaleFemaleMiddle AgedAdultRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalJapanCalcitonin Gene-Related Peptide

Stichwörter der Autor:innen

chronic migraineepisodic migrainefremanezumabreal-world data

Substanzen

fremanezumabAntibodies, MonoclonalCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Department of Neurology & Headache Center, Tominaga Hospital, Osaka City, Japan.

ORCID-Profile: Shoji Kikui

Zitieren

APA

Kikui, S., Daisuke, D., Miyahara, J., Sugiyama, H., Ota, K., Murakata, K., Kashiwaya, Y., & Takeshima, T. (2024). Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Medicine. https://doi.org/10.1093/pm/pnae050

Vancouver

Kikui S, Daisuke D, Miyahara J, Sugiyama H, Ota K, Murakata K, et al. Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Medicine. 2024. doi:10.1093/pm/pnae050

BibTeX
@article{Kikui2024,
  author = {Kikui, Shoji and Daisuke, Danno and Miyahara, Junichi and Sugiyama, Hanako and Ota, Kuniko and Murakata, Kenji and Kashiwaya, Yoshihiro and Takeshima, Takao},
  title = {Effectiveness of fremanezumab treatment in patients with migraine headache},
  journal = {Pain Medicine},
  year = {2024},
  doi = {10.1093/pm/pnae050}
}
Kostenlos starten →